Karmanos supports Michigan’s Clinical Trial Awareness Day
Friday, February 01, 2013
|Pictured are Anthony Shields, M.D., Ph.D., and State Rep. Gail Haines.
Several members of the Karmanos Cancer Institute traveled to the State Capitol in Lansing on Jan. 30 to participate in Michigan’s first Clinical Trial Awareness Day.
Organized by State Rep. Gail Haines, R-Waterford, her goal was to call attention to the more than 3,400 clinical trials being conducted in Michigan. "These trials can speed the healing time or even cure a disease, which is one of the main reasons this day is so important."
Participating in a press conference, Anthony Shields, M.D., Ph.D., associate center director, Clinical Sciences and Research, Karmanos Cancer Institute, spoke about the importance of cancer clinical trials which lead to developing the next standards of care.
He noted that out of the 33 cancer-fighting drugs most recently approved by the U.S. Food and Drug Administration, 16 were tested at the Karmanos Cancer Institute and available to our patients first.
“Karmanos is truly at the forefront of developing medications and treatments that other hospitals and health care organizations will follow in the future,” Dr. Shields said. “When appropriate, we encourage our patients to take part in a clinical trial. Ultimately, this helps improve cancer therapy and the quality of life for our patients.”
In addition to the medical advances resulting from clinical trials, State Rep. Haines said they have had a positive impact on the economy. A study by Archstone Consulting found that in 2008 the clinical trial industry supported more than 95,000 jobs throughout Michigan.
"I hope that this day draws attention to the great work that is happening in our state, and I am dedicated to continuing to raise awareness and work toward making Michigan a research-friendly environment."
Dr. Shields thanked State Rep. Haines for her leadership and encouraged all Michigan legislators to support a pro-research climate in the state. Also representing Karmanos were: Scott Boerner, research assistant from the Department of Oncology, Carol Christner, director, Government Relations and Helen Peck, executive director, Clinical Trials Office.